Mark G. Lebwohl, MD

Biologics, JAK inhibitors, and evolving treatment paradigms headline the Fall Clinical 2025 agenda.

If passed, the Safe Step Act could reduce treatment delays by prohibiting step therapy for FDA-labeled, guideline-supported agents.

Experts in dermatology share closing thoughts on the management of plaque psoriasis.

Drs Mark Lebwohl and Saakshi Khattri review recent advancements and emerging therapies in development for plaque psoriasis treatment.

Mark Lebwohl, MD, discusses the rapid expansion of therapeutic options, including targeted drugs like JAK inhibitors and IL-13 treatments for atopic dermatitis, paralleling the progress seen in psoriasis treatment over the last decade.

Mark Lebwohl, MD, emphasizes the importance of considering various factors, including severity of itch and interference with sleep, when determining treatments for patients with atopic dermatitis, even with presentation may not include typical symptoms.

Saakshi Khattri, MD, and Mark Lebwohl, MD, provide insight on the significance of steroid-free treatment options for the management of pediatric patients with plaque psoriasis and address unique considerations and challenges treating patients with skin of color.

Expert dermatologists highlight the use of nonsteroidal topical therapies, roflumilast and tapinarof, for the management of plaque psoriasis.

Mark Lebwohl, MD, and Saakshi Khattri, MD, examine the use of spesolimab in various diseases, including generalized pustular psoriasis (GPP), and comment on the use and safety of deucravacitinib.

Drs Mark Lebwohl and Saakshi Khattri review the significance of long-term data of bimekizumab for plaque psoriasis management.

Experts in dermatology discuss the use of bimekizumab in clinical practice for plaque psoriasis as well as its off-label use.

Saakshi Khattri, MD, and Mark Lebwohl, MD, share key insights on recent biologic, topical, and oral treatment approvals for the management of plaque psoriasis.

Mark Lebwohl, MD, spoke with Dermatology Times about his talk on IL-17 inhibitors.

Erin Boh, MD, emphasizes the importance of patient empowerment and physician education surrounding the management of GPP.

Experts in dermatology hypothesize about the management of patients with chronic vs acute GPP episodes.

Erin Boh, MD, discusses the role of steroid administration and withdrawal as a trigger for GPP, highlighting the importance of physician awareness of external influences initiating this condition.

Experts in dermatology provide insight into the importance of multidisciplinary care in the management of patients with generalized pustular psoriasis (GPP).

Erin Boh, MD, shares her opinion on the importance of proactively stocking and streamlining generalized pustular psoriasis (GPP) medication pathways due to emergent care requirements of GPP.

Mark Lebwohl, MD, discusses the utility of spesolimab, the only FDA-approved treatment for the management of patients with from generalized pustular psoriasis (GPP), highlighting the rapid efficacy of this therapy.

Erin Boh, MD, presents the case of a 60-year-old African American woman with generalized pustular psoriasis (GPP) covering her medical history, initial presentation, potential disease trigger, highlighting important comorbidities of concern and their impact on treatment selection.

Mark Lebwohl, MD, discusses his SDPA Annual Summer Dermatology Conference session, "Inflammatory Dermatoses: A Case-Based Review."

The intention is to expedite the development and review of the drug helping adults with generalized pustular psoriasis.

Mark Lebwohl, MD said it is a step forward for patients diagnosed with generalized pustular psoriasis.

Drs Mark G. Lebwohl and Alice B. Gottlieb discuss future expectations in the treatment of plaque psoriasis.

Mark G. Lebwohl, MD, and Alice B. Gottlieb, MD, PhD, discuss gaps in care for the treatment of plaque psoriasis.

Dr Mark Lebwohl provides insight into the educational needs of both patients and providers surround the utilization of spesolimab and its importance in the management of patients with generalized pustular psoriasis.

Mark G. Lebwohl, MD, comments on the clinical implications of the recent approval of spesolimab for the treatment of generalized pustular psoriasis.

An expert in dermatology presents the case of a 64-year-old female with a long history of plaque psoriasis, focusing on her disease severity and age-related management considerations.

Expert dermatologists discuss the risk of candidiasis with IL-17 inhibitors when managing plaque psoriasis and how to manage candidiasis.

Drs Mark G. Lebwohl and Alice B. Gottlieb discuss the novel mechanism of bimekizumab and how it can change the treatment landscape for plaque psoriasis.